ERBB2 and breast carcinoma: Research indicates that breast cancer exhibits considerable heterogeneity, with distinct molecular subtypes, such as luminal A, luminal B, HER2-enriched, and triple-negative breast cancer (TNBC), each having different biological behaviours and responses to treatment.3,10 This heterogeneity poses challenges in developing effective treatment strategies tailored to individual patients.